Summit Therapeutics to explore further clinical development of ivonescimab

Summit Therapeutics announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting in Barcelona, Spain, including two presentations and one poster featuring updated ivonescimab data in advanced triple-negative breast cancer, recurrent / metastatic head and neck squamous cell carcinoma, and metastatic microsatellite-stable colorectal cancer. Each trial from which the data was generated was a Phase II study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso. Based on the results of these Phase II data sets as well as data announced earlier in 2024, including early-stage non-small cell lung cancer and biliary tract cancer, Summit intends to explore further clinical development of ivonescimab in solid tumor settings outside of metastatic non-small cell lung cancer, the company’s current area of focus in its Phase III clinical trials.